Nothing Special   »   [go: up one dir, main page]

Gore et al., 2005 - Google Patents

Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis

Gore et al., 2005

View PDF
Document ID
2694309200669423570
Author
Gore J
Silver R
Publication year
Publication venue
Annals of the Rheumatic Diseases

External Links

Snippet

METHODS AND RESULTS We performed a retrospective chart review of 10 patients with SSc seen at a tertiary care referral centre who were offered sildenafil after standard treatments (calcium channel blockers, α blockers, angiotensin converting enzyme (ACE) …
Continue reading at www.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Similar Documents

Publication Publication Date Title
Gore et al. Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis
Gouveia et al. Ankylosing spondylitis and uveitis: overview
Braun et al. Biologic therapies in the spondyloarthritis: new opportunities, new challenges
Ikeda et al. Aspects of early arthritis. Biological therapy in early arthritis–overtreatment or the way to go?
Zweers et al. Tenascin-X: a candidate gene for benign joint hypermobility syndrome and hypermobility type Ehlers-Danlos syndrome?
Greenwald et al. Paediatric rheumatology
Rinaldi et al. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response
Morton Pagetic hydrocephalus treated with zoledronate
Rothschild et al. Whale of a tale
Kashiwagura et al. AB0196 THE ASSOCIATION BETWEEN OSTEOPOROSIS AND FUNCTIONAL IMPAIRMENT EVALUATED BY THE LOCOMO25 IN RHEUMATOID ARTHRITIS
Moraitis et al. Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus and Juvenile Dermatomyositis
Tofiq EVALUATION OF TL1A DIAGNOSTIC AND PROGNOSTIC VALUES IN ANKYLOSING SPONDYLITIS PATIENTS; IN SULAYMANIYAH GOVERNORATE
Page Humira (Adalimumab) AHM
Gils SP0082 Immunogenicity of biologics in inflammatory bowel diseases
Austad Patient reported outcomes in rheumatoid arthritis. Data from the Oslo Rheumatoid Arthritis Register
Cusa et al. Correlation Between the Auscan Index (Ai) and Strength, Dexterity and Function Tests in Patients With Primary Osteoarthritis of the Hand (Poah): 75
Cerda-Téllez et al. INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENT IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (IIM): 46
Baraliakos et al. Spondyloarthritis
Diamanti et al. Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and
Eliana et al. EVALUATION OF INFLIXIMAB IN THE TREATMENT OF ACTIVE JUVENILE RHEUMATOID ARTHRITIS (JRA): 43
Ralha et al. EFFICACY AND TOLERABILITY OF CELECOXIB 200 mG BID VERSUS DICLOFENAC 75 mG BID IN ACUTE LOW BACK PAIN: 62
Huizinga et al. Clinical Reviews
Puertas et al. CASE REPORT: REMISSION OF THE ADULT ONSET STILL DISEASE, IN A YOUNG MALE PATIENT TREATED WITH ETANERCEPT: 44
Virkki A clinical and health economical observational study of anti-tumor necrosis factor therapy in the treatment of rheumatoid arthritis in Finland
Quintero et al. GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR IS ANABOLIC AND INTERLEUKIN-1β CATABOLIC AGENT FOR Rat AC: 70